Eden advertises $199/month for compounded tirzepatide, but a required $99/month membership brings the recurring total to $298. We break down all fees, compare like-for-like month-to-month rates, and show the 12-month cost against plans with and without separate membership charges.

Eden charges $99/month for semaglutide medication plus a required $99/month membership—$198 total every month. We break down the two-part billing, first-month discount, renewal costs, and head-to-head comparison with PlexusDx's $189 all-inclusive rate.

Eden charges $198/month for semaglutide or $298 for tirzepatide (medication plus required membership). Three platforms deliver the same compounded GLP-1s at lower all-in monthly costs, with different billing structures, commitment options, and guarantees.

Eden's two-charge billing ($198–$298/month total) and monthly-only plans differ structurally from PlexusDx's single all-inclusive charge and multi-month commitment options. This guide walks through the practical transfer steps, cost implications, and service trade-offs when moving between providers.

Several telehealth programs advertise $99 monthly semaglutide. We compare Eden, Found, Mochi Health, and others against PlexusDx, normalizing introductory rates, membership fees, and prepay commitments to show the true recurring cost over 12 months.

Eden charges $99/month for semaglutide or $199/month for tirzepatide, plus a required $99/month membership fee—two separate recurring charges. Here's the all-in cost, the first-month discount, and how it compares over twelve months.

Eden's two-charge membership model costs $198/month for semaglutide, while PlexusDx delivers the same compound for $189/month with no separate fee. This breakdown compares structure, all-in pricing, format options, and cancellation terms for patients considering the switch.

Henry Meds and Eden both offer compounded semaglutide and tirzepatide in oral and injectable forms, but billing structures, month-to-month rates, and all-in costs differ substantially.

Eden offers injection-only GLP-1s at flat monthly rates with required membership. For higher-dose patients needing flexibility, format options, or predictable committed-term costs, structural differences matter. Evidence-based comparison of Eden versus PlexusDx for maintenance-phase therapy.

Eden charges $99 for medication plus a required $99/month membership ($198–$298 all-in). We compare Eden's two-part billing to single-charge programs and examine whether the structure suits no-membership-fee preferences.

Eden charges $198/mo for semaglutide, $298/mo for tirzepatide (medication plus mandatory membership), month-to-month only. PlexusDx runs $189/$289 month-to-month or lower with prepaid terms. Both allow cancellation; Eden adds a weight-loss pledge, PlexusDx offers oral and microdose routes.

Eden charges $198–$298/month (medication plus required membership); Embody charges $299–$349/month (single flat rate). Both offer compounded semaglutide and tirzepatide injections with cancel-anytime terms, but their billing structures and service models differ substantially.

Eden sells standard-dose injections with a results pledge; Remedy Meds sells microdose GLP-1 with unlimited visits. Neither structure dominates every priority—this comparison maps what each program includes, what it costs, and where PlexusDx fits the same decisions.

Eden is a telehealth platform offering GLP-1 prescription services. This guide evaluates Eden's operational model, clinical safeguards, and how to assess whether its approach aligns with your healthcare needs and medication sourcing preferences.

This independent editorial comparison of Hers and Eden separates Eden's advertised medication price from its verified all-in monthly cost once membership is added, explains its monthly billing and money-back warranty model, and adds the pathway-level genetic context neither telehealth brand measures for you.

Henry Meds and Eden both advertise low headline prices that differ from the real all-in cost. This independent editorial comparison lays their published pricing side by side, verified July 2026, and adds the pathway-level genetic baseline that neither program actually measures.

Mochi Health leans on insurance support while Eden is a cash-pay compounded service, and that difference shapes the whole experience. This independent review contrasts the two models, their pricing, and the inherited metabolic factor neither program measures before prescribing GLP-1 therapy.

This cost guide separates what Eden actually charges from the price it advertises. It breaks the monthly total into medication, the required membership fee, and the first-month promotion, projects a full year of spend, and sets that structure side by side with PlexusDx flat month-to-month pricing and formats.

This editorial explains what discounts really mean in cash-pay GLP-1 telehealth, where Eden publishes its variable pricing, and which eligibility factors, from compound choice to subscription tier, actually move the total you pay. It then contrasts that model with PlexusDx flat monthly rates and posted, tier-free product pricing.

This balanced review asks whether Eden is a legitimate GLP-1 telehealth provider by examining clinician licensing, the 503A compounding pathway, and clinical oversight. It lays out the verification steps that let you judge any telehealth brand yourself, then explains the genetic pathway context PlexusDx adds beyond credentialing.

Eden and Henry Meds both prescribe GLP-1 therapy but split on medication format and how they price it. This independent review compares injectable versus oral options, membership and prepaid structures, and the genetic factor neither program measures before a prescription is written.

Hers and Eden reach GLP-1 weight management from different directions, one a broad consumer subscription brand and one a focused compounded-pharmacy service. This independent review contrasts their two models, their pricing transparency, and the inherited metabolic factor that neither program actually measures before a prescription is written.

Wegovy is a specific brand-name product, so shoppers searching Eden Wegovy are often asking whether Eden supplies that brand or a compounded alternative. This independent review explains the difference, how Eden's telehealth model handles the request, general cost ranges, and the genetic context prescribing overlooks.

Subscription hides several moving parts in the GLP-1 market: a recurring membership, a recurring medication charge, and rules about when each begins. This independent review takes the Eden model apart along those lines, covers cancelation and the money-back warranty, and compares it with month-to-month pricing.

This review clarifies how Eden relates to Mounjaro, the branded FDA-approved tirzepatide, versus the compounded tirzepatide telehealth programs usually dispense. It covers the regulatory difference, how Eden delivers the pathway, the SURMOUNT trial evidence, and the genetic pathway context PlexusDx adds to any tirzepatide decision.

Zepbound is a specific brand of tirzepatide, so Eden Zepbound searches usually ask whether Eden supplies that brand or a compounded version. This independent review explains the difference, the telehealth 503A model, the true monthly cost, the SURMOUNT evidence, and the genetic variable involved.

This overview details the peptides behind Eden's GLP-1 program, how they are delivered and priced, and the incretin science behind semaglutide and tirzepatide. It then compares the broader PlexusDx peptide protocol range and explains the genetic pathway context its testing adds before any weight-management protocol begins.

Eden tirzepatide searches often come from people deciding between the branded drug and a compounded telehealth route. This independent review explains tirzepatide as a dual GIP/GLP-1 agonist, how Eden dispenses the compounded version, its true monthly cost, the SURMOUNT evidence, and the genetic baseline to consider.

Eden advertises a low medication price, but a required membership changes the math. This independent review separates Eden's headline figure from the true all-in monthly cost, walks through first-month, ongoing, and annual totals, and shows where month-to-month PlexusDx pricing lands by comparison.

This review separates Ozempic, the branded FDA-approved semaglutide, from the compounded semaglutide telehealth programs like Eden usually dispense. It explains the regulatory difference, details how Eden prices its semaglutide pathway, summarizes the STEP evidence, and describes the genetic pathway context PlexusDx adds to a semaglutide decision.